Evidence map›Paper›PMID 30722840›Full record

ReviewDeutsches Arzteblatt international2018

Hematological Malignancies in Adults With a Family Predisposition.

Tilmann Bochtler, Georg-Martin Haag, Sarah Schott, Matthias Kloor, Alwin Krämer, Carsten Müller-Tidow

Open access · greenAbstract readReview
In one paragraph

Review in Deutsches Arzteblatt international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Advances in the application of Raman spectroscopy in haematological tumours.Frontiers in bioengineering and biotechnology · 2022
    Review
  6. Review
  7. Prognostic Markers of Myelodysplastic Syndromes.Medicina (Kaunas, Lithuania) · 2020
    Review
  8. In Reply.Deutsches Arzteblatt international · 2019
    Article
  9. Supplemental Human Genetics Point of View.Deutsches Arzteblatt international · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tilmann BochtlerDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital and Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) Heidelberg, Germany; Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany; Section Head of Translational Gynecology, University Women's Hospital Heidelberg, German Cancer Consortium (DKTK), Heidelberg, Germany; Institute of Pathology, Department of Applied Tumor Biology, Heidelberg University Hospital, Heidelberg, Germany.
Georg-Martin Haag
Sarah Schott
Matthias Kloor
Alwin Krämer
Carsten Müller-Tidow
National Center for Tumor Diseases · DEHeidelberg University · DEUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSome hematological malignancies arise in persons with a hereditary predisposition. The hereditary nature of these diseases often goes unrecognized, particularly when symptoms begin in adulthood.

methodsThis review is based on pertinent publications retrieved by a selective search in PubMed.

resultsMany rare germline mutations have been identified that lead to acute leukemia and myelodysplastic syndromes. They differ from one another with respect to their penetrance, the age of onset of disease, and the clinical manifestations. In view of this heterogeneity, no uniform recommendations have yet been formulated for their diagnosis and treatment. The most common types of hematological malig- nancy with a hereditary predisposition are traceable to an underlying disturbance of DNA damage response and repair mechanisms and to mutations of hematological transcription factors. With regard to the selection of patients for testing, the con- sensus is that cytogenetic and molecular-genetic findings that are suspect for a hereditary predisposition, such as CEBPA and RUNX1 mutations, call for further investigation, as do any clinical features that are typical of tumor syndromes, or a positive family history. The knowledge that a hereditary predisposition may be present is highly stressful for patients; testing should only be carried out after the patient has received genetic counseling. The confirmation of a germline mutation always requires a comparison with healthy tissue. A fibroblast culture is recom- mended as the gold standard for this purpose.

conclusionThe detection of a hereditary predisposition to hematological neoplasia is often relevant to treatment and follow-up care: for example, it may motivate early allogeneic stem-cell transplantation. Counseling, predictive testing, and follow-up care are available to the patients' relatives as well.

Indexed as

CCAAT-Enhancer-Binding ProteinsCore Binding Factor Alpha 2 SubunitFibroblastsGenetic CounselingGenetic Predisposition to DiseaseGermanyGerm-Line MutationHematologic NeoplasmsHumansLeukemia, Myeloid, AcuteMutationMyelodysplastic SyndromesProspective StudiesRetrospective StudiesCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanCore Binding Factor Alpha 2 SubunitRUNX1 protein, human

Identifiers

PMID30722840
PMCPMC6375069
OpenAlexW2905222870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.